Association between use of sodium-glucose cotransporter-2 inhibitors and epilepsy: A population-based study using target trial emulation

Résumé fourni par la source

Objective: Preclinical studies in animals suggested potential neuroprotective effects of sodium-glucose co-transporter 2 inhibitors (SGLT-2i), but no epidemiological study has investigated the potential effects of SGLT-2i on epilepsy risk. We aimed to assess the association between use of SGLT-2i and epilepsy incidence. Research Design and Methods: We emulated a target trail comparing SGLT-2i and dipeptidyl peptidase 4 inhibitors (DPP-4i) based on the Yinzhou Regional Health Care Database. Cohorts of T2DM patients who were new users of SGLT-2i or DPP-4i were assembled. Inverse probability of treatment weighting (IPTW) and Cox model were applied to estimate the hazard ratio (HR) and 95% confidence interval (CI) of the association between use of SGLT-2i and incidence of epilepsy. Results: The final cohort included 24930 new users of SGLT-2i and 28924 initiators of DPP-4i. A total of 243 incident epilepsy cases occurred during a median follow-up of 2.0 (IQR, 0.8~3.3) years, with the incidence of epilepsy being 174.2 and 231.5 per 100,000 person-years in users of SGLT-2i and DPP-4i, respectively. After controlling potential confounding using IPTW, SGLT-2i use was associated with a lower incidence of epilepsy, with an HR of 0.71 (95% CI, 0.52–0.97). Various subgroup analyses and sensitivity analyses supported the results in primary analyses. Conclusions: SGLT-2i was associated with a reduced incidence of epilepsy in the study population. More studies are needed to confirm and replicate the study results.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.